CNS Pharmaceuticals Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ____________ to ______________ Commission file number:001-39126 CNS Pharmaceuticals, Inc.(Name of registrant as specified in its charter) Nevada82-2318545(State or other jurisdiction of Incorporation or Organization)(I.R.S. Employer identification No.) 2100 West Loop South, Suite 900Houston, Texas77027(Address of principal executive offices(Zip Code) 800-946-9185(Registrant’s telephone number, including area code) N/A(Former name or former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Title of Each ClassTrading SymbolName of Each Exchange on Which RegisteredCommon StockCNSPThe NASDAQ Stock Market LLC Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act: Large accelerated Filer☐Non-accelerated Filer☒Emerging Growth Company☐ Accelerated Filer☐Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ The number of shares outstanding of the registrant’s common stock, par value $0.001 per share, as of May 13, 2026 was 1,461,449. TABLE OF CONTENTS PART I FINANCIAL INFORMATION Item 1.Financial Statements3Balance Sheets as of March 31, 2026 and December 31, 2025 (unaudited)3Statements of Operations for the three months ended March 31, 2026 and 2025 (unaudited)4Statements of Stockholders’ Equity (Deficit) for the three months ended March 31, 2026 and 2025 (unaudited)5Statements of Cash Flows for the three months ended March 31, 2026 and 2025 (unaudited)6Notes to the Financial Statements (unaudited)7Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations14Item 3.Quantitative and Qualitative Disclosures About Market Risk18Item 4.Controls and Procedures18 PART II OTHER INFORMATION Item 1.Legal Proceedings19Item 1A.Risk Factors19Item 2.Unregistered Sales of Equity Securities and Use of Proceeds19Item 3.Defaults Upon Senior Securities19Item 4.Mine Safety Disclosures19Item 5.Other Information19Item 6.Exhibits20Signatures21 CNS Pharmaceuticals, Inc.Balance Sheets(Unaudited) CNS Pharmaceuticals, Inc.Statements of Operations(Unaudited) CNS Pharmaceuticals, Inc.Statements of Stockholders' EquityFor the three months ended March 31, 2026 and 2025(Unaudited) CNS Pharmaceuticals, Inc.Statements of Cash Flows(Unaudited) CNS Pharmaceuticals, Inc.Notes to the Financial Statements(Unaudited) Note 1 – Nature of Business CNS Pharmaceuticals, Inc. (“we”, “our”, the “Company”) is a biotechnology company organized as a Nevada corporation in July2017. In March 2026, we announced a new corporate strategy focused on developing innovative therapies for serious diseases. We areleveraging our executive team’s multi-functional experiences across high-value therapeutic areas to execute our new corporatestrategy, which also includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities forour legacy assets TPI 287 and Berubicin for which we have intellectual property rights under license agreement with Cortice and ownpursuant to a collaboration and asset purchase agreement with Reata. Note 2 – Summary of Significant Accounting Policies Basis of Presentation- The accompanying unaudited financial statements of the Company have been prepared in accordance withaccounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim unaudited financial information.Accordingly, they do not include all of the i